01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#HVO hVIVO PLC – Launch of full suite of hLAB standalone services September 30, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the official launch of the full suite of its hLAB service offering, its highly specialised virology and immunology laboratory services for preclinical and clinical drug development.   hLAB is an industry leader in virology and clinical trial support and has been providing laboratory services since 1989. In recent…

Continue reading

#POLB Poolbeg Pharma PLC – Results of Annual General Meeting May 11, 2023 – Posted in: Uncategorized

11 May 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces that at the Annual General Meeting held at 12:00pm today, all resolutions were duly passed.   – Ends –   Enquiries Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO   +44 (0) 207 183 1499 finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)  …

Continue reading

#HVO hVIVO PLC – Final results April 25, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its audited results for the 12 months ended 31 December 2022.   Financial highlights ·    Revenue up 30% to £50.7m (2021: £39.0m) ·    EBITDA increased threefold to £9.1m (2021: £2.9m) ·    EBITDA margins of 17.9% (2021: 7.4%), ahead of guidance due…

Continue reading

#HVO hVIVO PLC – Long Term Incentive Plan / PDMR Notification February 6, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that on 6 February 2023, the Company implemented a Long Term Incentive Plan (“LTIP”) for Yamin ‘Mo’ Khan, the Company’s Chief Executive Officer.   The LTIP has been designed to reward, incentivise and retain Mr Khan to deliver sustainable growth for shareholders.…

Continue reading

#HVO hVIVO PLC- £13.6m RSV antiviral contract November 10, 2022 – Posted in: Open Orphan (ORPH)

hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £13.6m contract with a US-based biopharmaceutical client to test its respiratory syncytial virus (“RSV”) antiviral candidate, using hVIVO’s established RSV Human Challenge Study Model                                 The Phase 2a double-blinded placebo-controlled human challenge trial will take place at…

Continue reading

#POLB Poolbeg Pharma PLC – HC Wainwright Global Investment Conference September 12, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

12 September 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that the Company’s Chairman, Cathal Friel, will be attending the HC Wainwright Global Investment Conference, which is taking place from 12-14 September at the Lotte New York Palace Hotel in New York City, NY, USA.   Enquiries   Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO    +44 (0)…

Continue reading